Adaptive Biotechnologies (ADPT) Receivables - Net (2018 - 2026)

Adaptive Biotechnologies has reported Receivables - Net for 9 years, with the latest figure at $48.3 million in Q1 2026.

• Quarterly Receivables - Net rose 10.86% year-over-year to $48.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $48.3 million (up 10.86% YoY) and the FY2025 annual result came in at $50.4 million, up 20.69% from the prior year.
• Receivables - Net retreated to $48.3 million in Q1 2026 per ADPT's latest filing, from $50.4 million in the prior quarter.
• Over five years, Receivables - Net peaked at $50.4 million in Q4 2025 and troughed at $22.5 million in Q1 2022.
• A 5-year average of $37.4 million and a median of $40.1 million in 2022 frame the typical range for Receivables - Net.
• The sharpest annual moves came in 2022 and 2023: Receivables - Net jumped 130.09% in 2022, then fell 5.21% in 2023.
• Over 5 years, Receivables - Net stood at $40.1 million in 2022, then retreated by 5.21% to $38.0 million in 2023, then increased by 9.91% to $41.7 million in 2024, then advanced by 20.69% to $50.4 million in 2025, then decreased by 4.07% to $48.3 million in 2026.
• According to Business Quant data, Receivables - Net over the past three periods registered $48.3 million, $50.4 million, and $44.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.